1. Home
  2. MEG vs URGN Comparison

MEG vs URGN Comparison

Compare MEG & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEG
  • URGN
  • Stock Information
  • Founded
  • MEG 2012
  • URGN 2004
  • Country
  • MEG United States
  • URGN United States
  • Employees
  • MEG N/A
  • URGN N/A
  • Industry
  • MEG Professional Services
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • MEG Consumer Discretionary
  • URGN Health Care
  • Exchange
  • MEG Nasdaq
  • URGN Nasdaq
  • Market Cap
  • MEG 764.0M
  • URGN 896.3M
  • IPO Year
  • MEG 2020
  • URGN 2017
  • Fundamental
  • Price
  • MEG $30.05
  • URGN $19.44
  • Analyst Decision
  • MEG Buy
  • URGN Strong Buy
  • Analyst Count
  • MEG 5
  • URGN 8
  • Target Price
  • MEG $32.00
  • URGN $28.50
  • AVG Volume (30 Days)
  • MEG 583.6K
  • URGN 1.0M
  • Earning Date
  • MEG 08-06-2025
  • URGN 08-07-2025
  • Dividend Yield
  • MEG N/A
  • URGN N/A
  • EPS Growth
  • MEG N/A
  • URGN N/A
  • EPS
  • MEG N/A
  • URGN N/A
  • Revenue
  • MEG $780,122,000.00
  • URGN $94,238,000.00
  • Revenue This Year
  • MEG $10.49
  • URGN $39.80
  • Revenue Next Year
  • MEG $7.12
  • URGN $108.94
  • P/E Ratio
  • MEG N/A
  • URGN N/A
  • Revenue Growth
  • MEG 17.79
  • URGN 10.85
  • 52 Week Low
  • MEG $10.51
  • URGN $3.42
  • 52 Week High
  • MEG $34.56
  • URGN $21.02
  • Technical
  • Relative Strength Index (RSI)
  • MEG 74.17
  • URGN 58.49
  • Support Level
  • MEG $26.60
  • URGN $18.65
  • Resistance Level
  • MEG $28.34
  • URGN $20.11
  • Average True Range (ATR)
  • MEG 1.93
  • URGN 1.20
  • MACD
  • MEG 0.34
  • URGN -0.24
  • Stochastic Oscillator
  • MEG 82.09
  • URGN 60.08

About MEG Montrose Environmental Group Inc.

Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: